Cargando…

Targeted rescue of cancer-associated IDH1 mutant activity using an engineered synthetic antibody

We have utilized a high-diversity phage display library to engineer antibody fragments (Fabs) that can modulate the activity of the enzyme isocitrate dehydrogenase 1 (IDH1). We show that a conformation-specific Fab can reactivate an IDH1 mutant associated with brain tumors. The results show that thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rizk, Shahir S., Mukherjee, Somnath, Koide, Akiko, Koide, Shohei, Kossiakoff, Anthony A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429742/ https://www.ncbi.nlm.nih.gov/pubmed/28373671 http://dx.doi.org/10.1038/s41598-017-00728-1

Ejemplares similares

Engineering synthetic antibody binders for allosteric inhibition of prolactin receptor signaling
por: Rizk, Shahir S, et al.
Publicado: (2015)

T Cell Receptor-Like Recognition of Tumor In Vivo by Synthetic Antibody Fragment
por: Miller, Keith R., et al.
Publicado: (2012)

A portable RNA sequence whose recognition by a synthetic antibody facilitates structural determination
por: Koldobskaya, Yelena, et al.
Publicado: (2010)

Engineered Ultra-High Affinity Synthetic Antibodies for SARS-CoV-2 Neutralization and Detection
por: Slezak, Tomasz, et al.
Publicado: (2021)

Mechanism of disease and therapeutic rescue of Dok7 congenital myasthenia
por: Oury, Julien, et al.
Publicado: (2021)

Selective and noncovalent targeting of RAS mutants for inhibition and degradation
por: Teng, Kai Wen, et al.
Publicado: (2021)

Allosteric Control of Ligand Binding Affinity Using Engineered Conformation-Specific Effector Proteins
por: Rizk, Shahir S., et al.
Publicado: (2011)

Engineering of a synthetic antibody fragment for structural and functional studies of K(+) channels
por: Rohaim, Ahmed, et al.
Publicado: (2022)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

CBMS-1 TARGETING GLUTAMINE METABOLISM IN IDH-MUTANT GLIOMAS
por: Ohba, Shigeo, et al.
Publicado: (2022)

Monobodies and other synthetic binding proteins for expanding protein science
por: Sha, Fern, et al.
Publicado: (2017)

Proof of dual-topology architecture of Fluc F(-) channels with monobody blockers
por: Stockbridge, Randy B., et al.
Publicado: (2014)

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
por: DiNardo, Courtney D., et al.
Publicado: (2022)

A synthetic intrabody based selective and generic inhibitor of GPCR endocytosis
por: Ghosh, Eshan, et al.
Publicado: (2017)

Optimizing Production of Antigens and Fabs in the Context of Generating Recombinant Antibodies to Human Proteins
por: Zhong, Nan, et al.
Publicado: (2015)

Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
por: Park, Jong-Whi, et al.
Publicado: (2019)

Development, structure, and mechanism of synthetic antibodies that target claudin and Clostridium perfringens enterotoxin complexes
por: Orlando, Benjamin J., et al.
Publicado: (2022)

Atomic structure of the eukaryotic intramembrane Ras methyltransferase ICMT
por: Diver, Melinda M., et al.
Publicado: (2018)

Selective Targeting of SH2 Domain–Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies
por: Kükenshöner, Tim, et al.
Publicado: (2017)

Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy
por: Hattori, Takamitsu, et al.
Publicado: (2023)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants
por: Khan, Imran, et al.
Publicado: (2022)

ETO family protein Mtgr1 mediates Prdm14 functions in stem cell maintenance and primordial germ cell formation
por: Nady, Nataliya, et al.
Publicado: (2015)

Zinc binding alters the conformational dynamics and drives the transport cycle of the cation diffusion facilitator YiiP
por: Lopez-Redondo, Maria, et al.
Publicado: (2021)

Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation
por: Sha, Fern, et al.
Publicado: (2023)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
por: Khurshed, Mohammed, et al.
Publicado: (2018)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Facile target validation in an animal model with intracellularly expressed monobodies
por: Gupta, Ankit, et al.
Publicado: (2018)

Structure of active β-arrestin1 bound to a G protein-coupled receptor phosphopeptide
por: Shukla, Arun K., et al.
Publicado: (2013)

A Rapid and Sensitive Microfluidics-Based Tool for Seroprevalence Immunity Assessment of COVID-19 and Vaccination-Induced Humoral Antibody Response at the Point of Care
por: Rajsri, Kritika Srinivasan, et al.
Publicado: (2022)

Induction of sarcomas by mutant IDH2
por: Lu, Chao, et al.
Publicado: (2013)

Oligosarcomas, IDH-mutant are distinct and aggressive
por: Suwala, Abigail K., et al.
Publicado: (2021)

Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma
por: Ruiz-Rodado, Victor, et al.
Publicado: (2020)

Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma
por: Shi, Diana D., et al.
Publicado: (2023)

Mutant IDH1 is required for IDH1 mutated tumor cell growth
por: Jin, Genglin, et al.
Publicado: (2012)

Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM
por: Pasquini, Luca, et al.
Publicado: (2021)

Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors
por: Akkapeddi, Padma, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_heograi0mqr3kucpn6d1iv1vdu